Immunome (IMNM)
Develops targeted oncology drugs across ADCs, radioligands and small molecules.
argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing
argenx NASDAQ: ARGX reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients with immune-mediated necrotizing myopathy, or IMNM, and dermatomyositis, or DM.
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011) Patient improvements observed early and sustained throughout study; consistent treatment effect across IMNM and DM First Phase 3 study to show statistically significant and clinically meaningful improvements in disease activity in IMNM, a subtype with no approved therapy argenx to host a conference call on August 17 th at 2:30 PM CET/ 8:30 AM ET August 17, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis. Study met its primary endpoint (p=0.0011) In the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population, patients treated with efgartigimod demonstrated statistically significant and clinically meaningful 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 versus placebo (47.95 vs 32.56).
Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon
I am maintaining my "Strong Buy" rating on Immunome (IMNM). This decision is driven by FDA acceptance of varegacestat's NDA and a PDUFA date set for April 2027. The company's pipeline is diversified, with IM-1021 [ROR1 ADC] in phase 1 for B-cell lymphoma/solid tumors and initial data expected in 2026. The proprietary HC74 TOP1i payload in IM-1021 aims for best-in-class efficacy, targeting resistance and bystander effects beyond Merck's ROR1 ADC.
Atika Capital Management LLC Sells 71,441 Shares of Immunome, Inc. $IMNM
Atika Capital Management LLC lessened its holdings in Immunome, Inc. (NASDAQ: IMNM) by 21.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 262,900 shares of the company's stock after selling 71,441 shares during the quarter. Atika Capital
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-3050, an investigational FAP-targeted radioligand therapy being evaluated in patients with FAP-expressing advanced solid tumors.“FAP is a high-potential target with expression in 75% of solid tumors,” said Bob Lechleider, M.D., Chi.
What This Immunome Sale Means a Day Before a Big FDA Milestone
An Immunome insider sold 100,000 shares for $2.4 million based on weighted average prices on July 6, 2026 and July 7, 2026. The transaction represents 32% of the insider's total equity holdings in the company.
Immunome Stock Up 32% in a Month: Here's What You Should Know
IMNM jumps 32% in a month. This comes as the FDA accepts varegacestat's NDA for desmoid tumors, with an approval decision expected by April 2027.
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on July 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 344,000 shares of common stock to seventeen new employees under the Company's 2024 In.
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
[url="]Immunome, Inc.[/url] (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today a
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1617, a potential first-in-class ADC directed at an undisclosed solid tumor target and incorporating HC74, Immunome's proprietary TOP1 inhibitor payload. “The first patient dosed with IM-1617 is a significant milestone for Immunom.
Immunome, Inc. (IMNM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Immunome, Inc. (IMNM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Immunome: Varegacestat Is The Beachhead, But The ADC Engine Is The Thesis
Immunome is evolving into a multi-asset targeted oncology platform, anchored by varegacestat's strong Phase 3 desmoid tumor data and an NDA submission. IMNM's cash position of $582.7M supports operations through 2028, enabling pipeline acceleration and mitigating near-term dilution risk. Varegacestat's efficacy (HR 0.16, ORR 56%) positions IMNM to challenge Ogsiveo in desmoid tumors, with broader TAM potential in ADCs and radioligand therapies.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on June 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 353,000 shares of common stock to twenty new employees under the Company's 2024 Induc.
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
[url="]Immunome, Inc.[/url] (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today a
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced detailed efficacy and safety results from RINGSIDE, the global, randomized, double-blind, placebo-controlled Phase 3 trial of varegacestat in patients with progressing desmoid tumors. The data are being presented today in an oral abstract session at the 2026 American Society of Clinical Oncology (ASCO) Annual.
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
[url="]Immunome[/url], Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today ann
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome's management will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 10:40 a.m. EDT. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.immunome.com. The webca.
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended March 31, 2026, and provided a business update. “This quarter reflects the progress we are making in building Immunome into a multi-program targeted oncology company,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome. “The NDA submission for v.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on May 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 450,000 shares of common stock to nineteen new employees under the Company's 2024 Indu.